Applied Filters
European Commission targets alleged ‘pay-for-delay’ with pharma fines
The European Commission’s competition directorate has levied fines totalling €146 million ($195 million) against originator pharmaceutical company Lundbeck and several producers of generics drugs.
Hi-tech and life sciences dominate at EPO awards
The inventor of the world’s first flat-panel liquid crystal display, Martin Schadt, was among a number of winners at the European Patent Office European Inventor Award 2013.
Actavis to buy Warner Chilcott
Actavis announced on May 20 it will acquire specialty pharmaceutical company Warner Chilcott plc in a deal worth an estimated $5 billion.
Ideas Matter: the importance of IP in the fight against cancer
On May 14, healthcare experts met in London to share and discuss developments in cancer detection, prevention, treatment and maintenance, and how IP protection and management are vital in attracting investment.
Ideas Matter: Philips and Microsoft in life sciences
At the Ideas Matter roundtable last week LSIPR spoke to Maaike van Velzen, general manager of Philips Group Innovation’s IP and Standards division, about the importance of using IP to promote the company’s vision.
AstraZeneca loses Seroquel appeal
The UK Court of Appeal has upheld the High Court’s decision that AstraZeneca’s patent for a sustained release formulation of anti-psychotic drug quetiapine is invalid.
Orchid invests in new European pharma
Indian pharmaceutical company Orchid Chemicals and Pharmaceuticals has entered into a partnership with new European biopharmaceutical company Allecra Therapeutics.
OFT accuses GSK of market abuse over pay-for-delay deals
The UK Office of Fair Trading has accused GlaxoSmithKline of abusing its market dominance and infringing UK competition law by paying rivals to delay releasing generic versions of its anti-depressant Seroxat.
1st Annual Life Sciences Law Forum: what do we know about the Unitary Patent?
Day two of the 1st Annual Life Sciences Forum in London saw panellists discuss the European Unitary Patent and the Unified Patent Court.
India rejects Bayer plea over compulsory licence
India’s patent authorities have dealt a blow to German pharma company Bayer by refusing to overturn an order forcing the company to license one of its patented drugs.
